Skip to search formSkip to main contentSkip to account menu

NSC 192965

Known as: NSC-192965 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

spirogermanium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Spirogermanium: A new investigational drug of novel structure and lack of bone marrow toxicity
SummarySpirogermanium (NSC 192965) is a new metallic investigational anticancer drug of novel heterocyclic structure. Although… 
1990
1990
Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer
SummaryFifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or… 
1989
1989
Identification of microsomal metabolites of spirogermanium.
In the present study we report on the identification of two novel microsomal metabolites of the investigational anticancer agent… 
1986
1986
[Metastatic cancer of the prostate: phase II study of spirogermanium (NSC 192965)].
A phase II study of spirogermanium was conducted in a series of 15 patients with metastatic prostatic carcinoma. All the patients… 
1982
1982
Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.
Lethal and other biological effects of 2-aza-8-germanspiro[4,5]decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)